IC
LLY icon

Intersect Capital’s Eli Lilly LLY Stock Holding History

Intersect Capital’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$2.05M Sell
6,336
-4,084
-39% -$1.23M 0.62% 30
2022
Q1 		$2.98M Sell
10,420
-387
-4% -$99.6K 0.57% 32
2021
Q4 		$2.98M Sell
10,807
-4,173
-28% -$1.06M 0.55% 36
2021
Q3 		$3.46M Buy
14,980
+228
+2% +$56.3K 0.59% 33
2021
Q2 		$3.39M Buy
14,752
+128
+0.9% +$25.7K 0.6% 31
2021
Q1 		$2.73M Buy
14,624
+316
+2% +$61.8K 0.55% 37
2020
Q4 		$2.42M Sell
14,308
-44
-0.3% -$6.57K 0.53% 40
2020
Q3 		$2.12M Buy
14,352
+3,368
+31% +$521K 0.57% 38
2020
Q2 		$1.8M Buy
10,984
+45
+0.4% +$6.91K 0.58% 40
2020
Q1 		$1.52M Buy
10,939
+1,675
+18% +$230K 0.6% 39
2019
Q4 		$1.22M Sell
9,264
-200
-2% -$23.2K 0.41% 52
2019
Q3 		$1.06M Sell
9,464
-406
-4% -$45.2K 0.4% 54
2019
Q2 		$1.09M Buy
9,870
+3,042
+45% +$358K 0.42% 52
2019
Q1 		$886K Buy
6,828
+396
+6% +$48.2K 0.37% 57
2018
Q4 		$744K Sell
6,432
-547
-8% -$61.1K 0.36% 62
2018
Q3 		$749K Hold
6,979
– – 0.33% 63
2018
Q2 		$595K Sell
6,979
-165
-2% -$13.6K 0.29% 68
2018
Q1 		$553K Hold
7,144
– – 0.29% 66
2017
Q4 		$603K Hold
7,144
– – 0.33% 62
2017
Q3 		$611K Buy
7,144
+300
+4% +$24.6K 0.35% 61
2017
Q2 		$563K Sell
6,844
-1,502
-18% -$123K 0.34% 61
2017
Q1 		$702K Sell
8,346
-168
-2% -$13.5K 0.61% 42
2016
Q4 		$626K Buy
8,514
+500
+6% +$37.2K 0.47% 52
2016
Q3 		$643K Sell
8,014
-6,306
-44% -$505K 0.51% 47
2016
Q2 		$1.13M Hold
14,320
– – 0.68% 38
2016
Q1 		$1.03M Buy
14,320
+2,863
+25% +$217K 0.65% 38
2015
Q4 		$965K Buy
11,457
+76
+0.7% +$6.31K 0.83% 29
2015
Q3 		$952K Hold
11,381
– – 0.87% 29
2015
Q2 		$950K Sell
11,381
-933
-8% -$71.1K 0.81% 31
2015
Q1 		$885K Buy
12,314
+444
+4% +$31.6K 0.68% 35
2014
Q4 		$819K Buy
+11,870
New +$801K 0.69% 32

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Intersect Capital's LLY Position: Q2 2022 in Review

Intersect Capital reduced its Eli Lilly (LLY) stake by 39% in Q2 2022, selling an estimated $1.23M and leaving 6,336 shares worth $2.05M. The position accounts for 0.62% of the portfolio, ranked #30.

Intersect Capital first reported a position in LLY in Q4 2014 and has held it in 31 quarters since. The position peaked at $3.46M in Q3 2021. 2,446 funds tracked by Wall St. Rank hold LLY as of Q2 2022.

  • Intersect Capital held 6,336 shares of Eli Lilly worth $2.05M as of Q2 2022.
  • Intersect Capital sold 4,084 Eli Lilly shares in Q2 2022, an estimated $1.23M.
  • Eli Lilly made up 0.62% of Intersect Capital's portfolio in Q2 2022, its #30 holding.
  • Intersect Capital first reported a position in Eli Lilly in Q4 2014 and has held it in 31 quarters since.
  • Intersect Capital's Eli Lilly position peaked at $3.46M in Q3 2021.
  • 2,446 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2022.

Based on Intersect Capital's 13F filing for Q2 2022, filed 2 Sep 2022.